• Sab. Feb 22nd, 2025

mount sinai

  • Home
  • A diabetes, heart failure and kidney disease medication (sotagliflozin) is the first of its kind to significantly reduce both heart attacks and strokes

A diabetes, heart failure and kidney disease medication (sotagliflozin) is the first of its kind to significantly reduce both heart attacks and strokes

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and…

Estrogen-Only Hormone Therapy may increase cancer risk while Estrogen-Progestin Combination may lower risk #ASCO24

For people who have been through menopause and have taken menopausal hormone therapy, conjugated equine estrogen (CEE) taken alone may increase the risk of developing and dying from ovarian cancer,…

Immune Cells Identified as Key Players in Brain Health

Using novel genetic and genomic tools, researchers at the Icahn School of Medicine at Mount Sinai have shed light on the role of immune cells called macrophages in lipid-rich tissues…